Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Lenalidomide Maintenance Significantly Improves Survival Figures in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Final Results of a Multicentre Phase II Trial

Blood (2016) 128 (22): 474.

https://doi.org/10.1182/blood.V128.22.474.474

Published: 2016

Journal Articles

Lenalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) in Patients with Chemosensitive Relapse of Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT) or Experienced Relapse after Transplantation: Results of a Multicentre Phase II Trial

Andrés J.M. Ferreri, Marianna Sassone, Marianna Chiozzotto, Michele Spina, MD, Alessandra Tucci, Alice Di Rocco, Alberto Fabbri, Caterina Stelitano, Maurizio Frezzato, Renato Zambello, Giovanni Bertoldero, Chiara Rusconi, MD, Annalisa Arcari, Lydia Scarfo, Silvia Govi, Maurilio Ponzoni, MD, Francesco Zaja, MD

Blood (2015) 126 (23): 1547.

https://doi.org/10.1182/blood.V126.23.1547.1547

Published: 2015

Journal Articles

Interim Analysis Of An Ongoing PHASE II Trial Assessing Safety and Efficacy Of Lenalidomide Maintenance In Patients With Chemosensitive Relapse Of Diffuse Large B-CELL Lymphoma (DLBCL)

Silvia Govi, MD, Marta Bruno Ventre, MD, Francesco Zaja, Alice Di Rocco, MD, Michele Spina, Daniele Vallisa, MD, Lydia Scarfo', MD, Marianna Chiozzotto, MD, Rosanna Cuccurullo, MD, Angelo Fama, MD, Andrés J.M. Ferreri, MD

Blood (2013) 122 (21): 3055.

https://doi.org/10.1182/blood.V122.21.3055.3055

Published: 2013

Journal Articles

Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

Marta Bruno Ventre, MD, Marco Foppoli, MD, Giovanni Citterio, MD, Giovanni Donadoni, MD, Maurilio Ponzoni, MD, Silvia Govi, MD, Lydia Scarfò, MD, Marianna Sassone, MD, Federico Caligaris -Cappio, MD, Prof., Andres J.M. Ferreri, MD, PhD

Blood (2013) 122 (21): 4365.

https://doi.org/10.1182/blood.V122.21.4365.4365

Published: 2013

Journal Articles

Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial

Andrés J. M. Ferreri, Silvia Govi, Markus Raderer, Antonino Mulè, Alessandro Andriani, Daniele Caracciolo, Liliana Devizzi, Fiorella Ilariucci, Stefano Luminari, Edi Viale, Leonhard Müllauer, Stefania Dell'Oro, Paolo Giorgio Arcidiacono, Maurilio Ponzoni, Caterina Patti

Blood (2012) 120 (18): 3858–3860.

https://doi.org/10.1182/blood-2012-06-438424

Published: 2012

Journal Articles

Safety and Activity of Intensive Short-Term Chemoimmunotherapy in HIV-Positive (HIV+) Patients (pts) with Burkitt Lymphoma (BL)

Marta Bruno Ventre, MD, Giovanni Donadoni, MD, Alessandro Re, MD, Michele Spina, MD, Chiara Cattaneo, Luca Fumagalli, MD, Silvia Mappa, MD, Silvia Govi, MD, Giuseppe Rossi, MD, Umberto Tirelli, MD, Andrés JM Ferreri, MD

Blood (2011) 118 (21): 2692.

https://doi.org/10.1182/blood.V118.21.2692.2692

Published: 2011

Journal Articles

Final Results of a Multicenter Phase II Trial with Translational Elements to Investigate the Possible Infective Causes of Ocular Adnexal Marginal Zone B-Cell Lymphoma (OAMZL) with Particular Reference to Chlamydia Species and the Efficacy of Doxycycline As First-Line Lymphoma Treatment (the IELSG#27 TRIAL)

Silvia Govi, MD, Riccardo Dolcetti, MD, Maurilio Ponzoni, MD, Elisa Pasini, RF, Silvia Mappa, MD, Marta Bruno Ventre, MD, Claudio Doglioni, MD, Francesco Bertoni, MD, Francesco Zaja, MD, Carlos Montalban, MD, PhD, Caterina Stelitano, MD, Maria Elena Cabrera, MD, Franco Cavalli, MD, Emanuele Zucca, MD, Andrés J.M. Ferreri, MD

Blood (2011) 118 (21): 267.

https://doi.org/10.1182/blood.V118.21.267.267

Published: 2011

Journal Articles

Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori -Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial)

Silvia Govi, MD, Caterina Patti, MD, Markus Raderer, MD, Alessandro Andriani, MD, Daniele Caracciolo, MD, Anna Guidetti, MD, Fiorella Ilariucci, MD, Stefano Luminari, MD, Antonino Mulè, MD, Edi Viale, MD, Paolo Giorgio Arcidiacono, MD, Maurilio Ponzoni, MD, Andrés J.M. Ferreri, MD

Blood (2011) 118 (21): 958.

https://doi.org/10.1182/blood.V118.21.958.958

Published: 2011

Journal Articles

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

Blood (2011) 117 (5): 1595–1604.

https://doi.org/10.1182/blood-2010-01-264275

Published: 2011

Includes: Supplemental data

Journal Articles

Post-Chemotherapy Brain Irradiation in Primary CNS Lymphomas: Impact on Survival of Different Fields and Doses.

Andres JM Ferreri, Chiara Verona, Letterio Salvatore Politi, Lucia Perna, Anna Chiara, Marco Foppoli, Giada Licata, Silvia Mappa, Fabio Ciceri, Piero Picozzi, Alberto Franzin, Silvia Govi, Maurilio Ponzoni, MD, Maria Rosa Terreni, Eugenio Villa, Michele Reni, M.D.

Blood (2009) 114 (22): 2696.

https://doi.org/10.1182/blood.V114.22.2696.2696

Published: 2009

Journal Articles

Array-CGH Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone Lymphomas

Blood (2008) 112 (11): 622.

https://doi.org/10.1182/blood.V112.11.622.622

Published: 2008

Journal Articles

A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type

Andres JM Ferreri, MD, Giuseppina Patrizia Dognini, M.D., Roberto Crocchiolo, M.D., Silvia Govi, M.D., Giada Licata, M.D., Maurilio Ponzoni, M.D., Antonio Giordano Resti, M.D., Letterio Salvatore Politi, M.D., Alberto Rosso, M.D., Eugenio Villa, M.D.

Blood (2008) 112 (11): 3062.

https://doi.org/10.1182/blood.V112.11.3062.3062

Published: 2008

Journal Articles

A Cumulative Series from 14 Western Countries Suggests That Rituximab Significantly Changed the Dismal Natural History of Intravascular Large B-Cell Lymphoma (IVL) .

Andres JM Ferreri, MD, Silvia Govi, M.D., Giuseppina Patrizia Dognini, M.D., Maria Bouzani, M.D., Claudia Ruth Bollinguer, M.D., Michel D’Incan, M.D., Emmanuel Delaporte, M.D., Mehdi Hamadani, M.D., Fabrice Jardin, M.D., Magdalena Martusewicz-Boros, M.D., Mauro Montanari, M.D., Arpad Szomor, M.D., Roberto Crocchiolo, M.D., Emanuele Zucca, M.D., Franco Cavalli, M.D., Maurilio Ponzoni, M.D.

Blood (2008) 112 (11): 2008.

https://doi.org/10.1182/blood.V112.11.2008.2008

Published: 2008

NARROW

Lenalidomide Maintenance Significantly Improves Survival Figures in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Final Results of a Multicentre Phase II Trial

Interim Analysis Of An Ongoing PHASE II Trial Assessing Safety and Efficacy Of Lenalidomide Maintenance In Patients With Chemosensitive Relapse Of Diffuse Large B-CELL Lymphoma (DLBCL)

Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial

Safety and Activity of Intensive Short-Term Chemoimmunotherapy in HIV-Positive (HIV+) Patients (pts) with Burkitt Lymphoma (BL)

Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori -Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial)

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

Post-Chemotherapy Brain Irradiation in Primary CNS Lymphomas: Impact on Survival of Different Fields and Doses.

Array-CGH Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone Lymphomas

A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type

A Cumulative Series from 14 Western Countries Suggests That Rituximab Significantly Changed the Dismal Natural History of Intravascular Large B-Cell Lymphoma (IVL) .

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only